36
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Tobacco control policies in the 21st century: achievements and open challenges

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Noncommunicable diseases (NCDs), including cancer, are responsible for almost 70% of all deaths worldwide. Tobacco use is a risk factor common to most NCDs. This article discusses tobacco control policies and highlights major achievements and open challenges to reduce smoking prevalence and attributable morbidity and mortality in the 21st century. The introduction of the WHO Framework Convention on Tobacco Control in 2005 has been a key achievement in the field and has already facilitated a drop in both smoking prevalence and exposure to secondhand smoke. Indicatively, the size of the worldwide population benefiting from at least one cost‐effective tobacco control policy has quadrupled since 2007. In addition, plain cigarette packaging has been successfully introduced as a tobacco control policy, surmounting efforts of the tobacco industry to challenge this based on trade and investment law. Nevertheless, tobacco control still faces major challenges. Smoking prevalence needs to be further reduced in a rather expedited manner. Smoke‐free environments should be extended, and the use of plain tobacco packaging with large pictorial health warnings for all tobacco products should be further promoted in some parts of the world. Some of these measures will require prompt determination and diligence. For example, bold political decisions are needed to significantly increase real prices of tobacco products through excise taxes, ban added ingredients that are currently used to increase the attractiveness of tobacco products and ban the tobacco industry's corporate social responsibility initiatives. Finally, the debate on harm reduction strategies for tobacco control still needs to be resolved.

          Abstract

          Tremendous, although insufficient, progress has been made on tobacco control during the past twenty years. Nevertheless, there are still open challenges, and several measures remain to be implemented soon: increasing tobacco taxes, banning the use of additives, implementing plain packaging, banning tobacco industry's corporate social responsibility activities, and counteracting the undermining tactics of the tobacco industry.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Smoking Is Associated With COVID-19 Progression: A Meta-analysis

          Abstract Introduction Smoking depresses pulmonary immune function and is a risk factor contracting other infectious diseases and more serious outcomes among people who become infected. This paper presents a meta-analysis of the association between smoking and progression of the infectious disease COVID-19. Methods PubMed was searched on April 28, 2020, with search terms “smoking”, “smoker*”, “characteristics”, “risk factors”, “outcomes”, and “COVID-19”, “COVID”, “coronavirus”, “sar cov-2”, “sar cov 2”. Studies reporting smoking behavior of COVID-19 patients and progression of disease were selected for the final analysis. The study outcome was progression of COVID-19 among people who already had the disease. A random effects meta-analysis was applied. Results We identified 19 peer-reviewed papers with a total of 11,590 COVID-19 patients, 2,133 (18.4%) with severe disease and 731 (6.3%) with a history of smoking. A total of 218 patients with a history of smoking (29.8%) experienced disease progression, compared with 17.6% of non-smoking patients. The meta-analysis showed a significant association between smoking and progression of COVID-19 (OR 1.91, 95% confidence interval [CI] 1.42-2.59, p = 0.001). Limitations in the 19 papers suggest that the actual risk of smoking may be higher. Conclusions Smoking is a risk factor for progression of COVID-19, with smokers having higher odds of COVID-19 progression than never smokers. Implications Physicians and public health professionals should collect data on smoking as part of clinical management and add smoking cessation to the list of practices to blunt the COVID-19 pandemic.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Global economic cost of smoking-attributable diseases

            Background The detrimental impact of smoking on health has been widely documented since the 1960s. Numerous studies have also quantified the economic cost that smoking imposes on society. However, these studies have mostly been in high income countries, with limited documentation from developing countries. The aim of this paper is to measure the economic cost of smoking-attributable diseases in countries throughout the world, including in low- and middle-income settings. Methods The Cost of Illness approach is used to estimate the economic cost of smoking attributable-diseases in 2012. Under this approach, economic costs are defined as either ‘direct costs' such as hospital fees or ‘indirect costs’ representing the productivity loss from morbidity and mortality. The same method was applied to 152 countries, which had all the necessary data, representing 97% of the world's smokers. Findings The amount of healthcare expenditure due to smoking-attributable diseases totalled purchasing power parity (PPP) $467 billion (US$422 billion) in 2012, or 5.7% of global health expenditure. The total economic cost of smoking (from health expenditures and productivity losses together) totalled PPP $1852 billion (US$1436 billion) in 2012, equivalent in magnitude to 1.8% of the world's annual gross domestic product (GDP). Almost 40% of this cost occurred in developing countries, highlighting the substantial burden these countries suffer. Conclusions Smoking imposes a heavy economic burden throughout the world, particularly in Europe and North America, where the tobacco epidemic is most advanced. These findings highlight the urgent need for countries to implement stronger tobacco control measures to address these costs.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Exposure to Secondhand Smoke Among Nonsmokers — United States, 1988–2014

              Exposure to secondhand smoke from burning tobacco products can cause sudden infant death syndrome, respiratory infections, ear infections, and asthma attacks in infants and children, and coronary heart disease, stroke, and lung cancer in adult nonsmokers ( 1 ). There is no risk-free level of secondhand smoke exposure ( 2 ). CDC analyzed questionnaire and laboratory data from the National Health and Nutrition Examination Survey (NHANES) to assess patterns of secondhand smoke exposure among U.S. nonsmokers. The prevalence of secondhand smoke exposure among U.S. nonsmokers declined substantially during 1988–2014, from 87.5% to 25.2%. However, no change in exposure occurred between 2011–2012 and 2013–2014, and an estimated one in four nonsmokers, or approximately 58 million persons, were still exposed to secondhand smoke during 2013–2014. Moreover, marked disparities persisted across population groups. Exposure prevalence was highest among nonsmokers aged 3–11 years (37.9%), non-Hispanic blacks (50.3%), and those who were living in poverty (47.9%), in rental housing (38.6%), or with someone who smoked inside the home (73.0%), or among persons who had less than a high school education (30.7%). Comprehensive smoke-free laws and policies for workplaces and public places and smoke-free rules for homes and vehicles can further reduce secondhand smoke exposure among all nonsmokers.
                Bookmark

                Author and article information

                Contributors
                efernandez@iconcologia.net
                Journal
                Mol Oncol
                Mol Oncol
                10.1002/(ISSN)1878-0261
                MOL2
                Molecular Oncology
                John Wiley and Sons Inc. (Hoboken )
                1574-7891
                1878-0261
                15 February 2021
                March 2021
                : 15
                : 3 ( doiID: 10.1002/mol2.v15.3 )
                : 744-752
                Affiliations
                [ 1 ] Tobacco Control Research Group, Epidemiology and Public Health Research Programme Institut d'Investigació Biomèdica de Bellvitge‐IDIBELL Barcelona Spain
                [ 2 ] Consortium of Centers for Biomedical Research on Respiratory Diseases (CIBERES) Madrid Spain
                [ 3 ] Center for Epidemiology and Health Policies Clínica Alemana School of Medicine Universidad del Desarrollo Santiago Chile
                [ 4 ] Evaluation and Intervention Methods Service Agència de Salut Pública de Barcelona Spain
                [ 5 ] Consortium of Centers for Biomedical Research on Epidemiology and Public Health, CIBERESP Madrid Spain
                [ 6 ] Institut d'Investigació Biomèdica de Sant Pau (IIB Sant Pau) Barcelona Spain
                [ 7 ] Tobacco Control Unit WHO Collaborating Center on Tobacco Control Institut Català d'Oncologia‐ICO Barcelona Spain
                [ 8 ] School of Medicine and Health Sciences Campus of Bellvitge, Universitat de Barcelona Spain
                Author notes
                [*] [* ] Correspondence

                E. Fernández, Tobacco Control Unit, WHO Collaborating Centre for Tobacco Control, Institut Català d'Oncologia‐ICO, L'Hospitalet de Llobregat, Barcelona 08908, Spain

                E‐mail: efernandez@ 123456iconcologia.net

                Author information
                https://orcid.org/0000-0002-1138-3292
                https://orcid.org/0000-0003-4402-2239
                https://orcid.org/0000-0002-0108-3288
                https://orcid.org/0000-0003-4239-723X
                Article
                MOL212918
                10.1002/1878-0261.12918
                7931122
                33533185
                349c2362-8881-4b51-96d8-27909b38f309
                © 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 16 November 2020
                : 11 January 2021
                : 12 January 2021
                Page count
                Figures: 2, Tables: 2, Pages: 9, Words: 13723
                Funding
                Funded by: Instituto de Salud Carlos III , open-funder-registry 10.13039/501100004587;
                Award ID: CIBERES CB19/06/00004
                Award ID: INT16/00211
                Award ID: INT17/00103
                Funded by: Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya , open-funder-registry 10.13039/501100002943;
                Award ID: 2017SGR319
                Award ID: 9015‐586920/2017
                Categories
                Review
                Reviews
                Custom metadata
                2.0
                March 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.9 mode:remove_FC converted:04.03.2021

                Oncology & Radiotherapy
                cancer,global health,health policy,noncommunicable diseases,smoking,tobacco control

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content149

                Cited by32

                Most referenced authors210